Synthetic lethality’s second wind

A burst of company presentations indicate the next wave of synthetic lethality programs is gaining momentum based on promising early data, more specific compounds and better-defined cancer patient populations.

The field is also attracting new funding and deals, and branching out to targets beyond the DNA damage response (DDR) pathway kinases that have dominated the scene...